The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes [Abstract]
No description supplied
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Default Conference proceeding |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2134/12377810.v1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|